Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Gains from Investment Securities (2021 - 2026)

Nuvectis Pharma has reported Gains from Investment Securities over the past 6 years, most recently at $847904.0 for Q1 2026.

  • Quarterly results put Gains from Investment Securities at $847904.0 for Q1 2026, changed 0.45% from a year ago — trailing twelve months through Mar 2026 was $847904.0 (changed 0.45% YoY), and the annual figure for FY2025 was $348281.0, changed 0.0%.
  • Gains from Investment Securities reached $847904.0 in Q1 2026 per NVCT's latest filing, up from $348281.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.1 million in Q3 2025 and bottomed at $226590.0 in Q1 2022.
  • Median Gains from Investment Securities over the past 5 years was $348281.0 (2023), compared with a mean of $480393.4.
  • The largest annual shift saw Gains from Investment Securities surged 554.88% in 2022 before it crashed 40.01% in 2025.
  • Over 5 years, Gains from Investment Securities stood at $311590.0 in 2022, then grew by 11.78% to $348281.0 in 2023, then changed by 0.0% to $348281.0 in 2024, then changed by 0.0% to $348281.0 in 2025, then surged by 143.45% to $847904.0 in 2026.
  • Business Quant data shows Gains from Investment Securities for NVCT at $847904.0 in Q1 2026, $348281.0 in Q4 2025, and $1.1 million in Q3 2025.